超越传统疫苗接种价值评估:需求与机遇
本文讨论传统疫苗经济评价仅关注免疫接种者避免的医疗费用等窄口径收益,指出近年研究识别出应纳入经济评价的额外接种收益,早期估计显示疫苗价值被显著低估,并对公共与私人疫苗政策及人类健康福利有重要影响;推进该新兴研究方向需更多更好数据,文章讨论有前景的数据来源、方法与待解决问题。
要点
- 传统疫苗经济评价聚焦窄口径收益,如免疫接种者避免的医疗费用。
- 近年研究识别出应纳入经济评价的额外接种收益,以反映疫苗的全部价值。
- 早期估计提示疫苗价值被显著低估;推进研究需更多更好数据。
核心结论
- 早期对更广泛接种收益规模的估计提示,疫苗接种的价值被显著低估,这对公共与私人疫苗政策及人类健康与福利具有重要影响。
研究设计与样本
- 本文为综述性文章,讨论疫苗经济评价中传统收益之外的更广泛收益、有前景的数据来源与方法以及需解决的研究问题。
主要发现
- 传统疫苗经济评价主要关注较窄的收益集合,如免疫接种者避免的医疗费用。
- 近年研究者识别出应纳入经济评价的额外接种收益,以反映疫苗的全部价值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 推进该新兴研究方向需更多更好数据;文章讨论有前景的数据来源与方法及需解决的研究问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Economic evaluations of vaccination traditionally focus on a relatively narrow set of vaccine benefits, such as averted medical care costs among those who are immunized. In recent years, researchers have identified additional vaccination benefits that should be incorporated into economic evaluations in order to reflect vaccination's full value. Early efforts to estimate the magnitude of these broader benefits suggest that vaccination has been substantially undervalued, which has important implications for public and private vaccine policy and human health and welfare. More and better data will be required to advance this emerging line of research on the value of vaccination. The article discusses promising data sources and methods and research questions needing to be addressed.
引用
- Bloom DE, Brenzel L, Cadarette D, et al. Moving beyond traditional valuation of vaccination: Needs and opportunities. Vaccine. 2016. PMID: 28017436. doi:10.1016/j.vaccine.2016.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。